218 related articles for article (PubMed ID: 34385595)
41. MORC2 promotes development of an aggressive colorectal cancer phenotype through inhibition of NDRG1.
Liu J; Shao Y; He Y; Ning K; Cui X; Liu F; Wang Z; Li F
Cancer Sci; 2019 Jan; 110(1):135-146. PubMed ID: 30407715
[TBL] [Abstract][Full Text] [Related]
42. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
43. N-myc downstream-regulated gene 1 inhibits the proliferation of colorectal cancer through emulative antagonizing NEDD4-mediated ubiquitylation of p21.
Zhang S; Yu C; Yang X; Hong H; Lu J; Hu W; Hao X; Li S; Aikemu B; Yang G; He Z; Zhang L; Xue P; Cai Z; Ma J; Zang L; Feng B; Yuan F; Sun J; Zheng M
J Exp Clin Cancer Res; 2019 Dec; 38(1):490. PubMed ID: 31831018
[TBL] [Abstract][Full Text] [Related]
44. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
[TBL] [Abstract][Full Text] [Related]
45. The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis.
Valverde A; Peñarando J; Cañas A; López-Sánchez LM; Conde F; Guil-Luna S; Hernández V; Villar C; Morales-Estévez C; de la Haba-Rodríguez J; Aranda E; Rodríguez-Ariza A
Oncotarget; 2017 Mar; 8(13):21754-21769. PubMed ID: 28423516
[TBL] [Abstract][Full Text] [Related]
46. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
Kim S; Kim N; Kang K; Kim W; Won J; Cho J
Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
[TBL] [Abstract][Full Text] [Related]
47. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer.
Yang L; Bhattacharya A; Li Y; Sexton S; Ling X; Li F; Zhang Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):184. PubMed ID: 35650607
[TBL] [Abstract][Full Text] [Related]
48. Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.
Narvi E; Vaparanta K; Karrila A; Chakroborty D; Knuutila S; Pulliainen A; Sundvall M; Elenius K
Sci Rep; 2018 Nov; 8(1):16579. PubMed ID: 30410004
[TBL] [Abstract][Full Text] [Related]
49. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
Yoon J; Koo KH; Choi KY
Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
[TBL] [Abstract][Full Text] [Related]
50. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
[TBL] [Abstract][Full Text] [Related]
51. A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR downstream signaling pathways in colorectal cancer.
Kong L; Zhang Q; Mao J; Cheng L; Shi X; Yu L; Hu J; Yang M; Li L; Liu B; Qian X
J Gastrointest Oncol; 2021 Aug; 12(4):1625-1642. PubMed ID: 34532116
[TBL] [Abstract][Full Text] [Related]
52. An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review.
Fornasier G; Francescon S; Baldo P
Adv Ther; 2018 Oct; 35(10):1497-1509. PubMed ID: 30218345
[TBL] [Abstract][Full Text] [Related]
53. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
E J; Xing J; Gong H; He J; Zhang W
Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806
[TBL] [Abstract][Full Text] [Related]
54. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
Iida M; Brand TM; Starr MM; Li C; Huppert EJ; Luthar N; Pedersen MW; Horak ID; Kragh M; Wheeler DL
Neoplasia; 2013 Oct; 15(10):1196-206. PubMed ID: 24204198
[TBL] [Abstract][Full Text] [Related]
55. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
56. Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
Dixon KM; Lui GY; Kovacevic Z; Zhang D; Yao M; Chen Z; Dong Q; Assinder SJ; Richardson DR
Br J Cancer; 2013 Feb; 108(2):409-19. PubMed ID: 23287991
[TBL] [Abstract][Full Text] [Related]
57. Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway.
Wang C; Yang M; Gu X; Gu Y
Bioengineered; 2021 Dec; 12(1):6594-6605. PubMed ID: 34516351
[TBL] [Abstract][Full Text] [Related]
58. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
59. Knockdown of NDRG1 promote epithelial-mesenchymal transition of colorectal cancer via NF-κB signaling.
Ma J; Gao Q; Zeng S; Shen H
J Surg Oncol; 2016 Sep; 114(4):520-7. PubMed ID: 27338835
[TBL] [Abstract][Full Text] [Related]
60. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]